Introduction {#Sec1}
============

Asthma is a serious global health problem affecting approximately 300 million people worldwide.^[@CR1],\ [@CR2]^ The estimated prevalence of people living with asthma ranges from 1 to 21% in adults and with up to 20% of children aged 6--7 years experiencing severe wheezing episodes within a year.^[@CR3],\ [@CR4]^

One of the main challenges in asthma control is adherence to pharmaceutical treatment. Generally, poor adherence is common across many chronic diseases such as asthma.^[@CR5],\ [@CR6]^ As it is not easy to test clinically for adherence, several questionnaires have been developed to assess adherence to medication.^[@CR7],\ [@CR8]^ These questionnaires are widely used in many countries. However, no information is available on treatment adherence of asthma patients in Latvia.

Several factors influence treatment adherence. Some of these factors are related to complexity of the therapy, fear of side effects of drugs, method of taking the drug, dosage regimen, adverse events, knowledge about the essence of the disease and its complications, illness perception and social support.^[@CR6],\ [@CR9],\ [@CR10]^ Especially, medical beliefs, cognitive and emotional perceptions have shown to be related to medical adherence.^[@CR11],\ [@CR12]^ Furthermore, individual asthma management might be improved by a better understanding of the types of beliefs or illness-related perceptions that are associated with low adherence to preventer medication.^[@CR13]^ Vrijens et al.'s proposed Ascertaining Barriers to Compliance (ABC) taxonomy conceptualizes adherence to medications in line with principles of behavioral and pharmacological science.^[@CR14]^ The ABC taxonomy defines the overarching concept of "medication adherence" as the process by which patients take their medication as prescribed and subdivides it into 3 essential elements: (A) initiation; (B) implementation, and (C) persistence. This subdivision outlines the sequence of events that have to occur for a patient to experience the optimal benefit from his or her prescribed treatment regimen.^[@CR14]^

Thus, comparing how well these factors predict treatment adherence in the currently available adherence scores, may give valuable insight in the questionnaire-of-choice for the Latvian asthma population in order to be implemented in clinical practice throughout the country.

The aim of this study was to test the association between adherence to asthma medication, control and medical beliefs, cognitive and emotional perceptions using three different validated questionnaires in Latvian asthma patients.

Results {#Sec2}
=======

The baseline characteristics of the study population are presented in Table [1](#Tab1){ref-type="table"}.Table 1Baseline characteristics of the study sampleMenWomenTotal(*n* = 85)(*n* = 264)(*n* = 352)*p*-valueAge, mean (SD)53.7 (17.4)58.7 (16.6)57.5 (16.9)0.017Education, %0.006 Basic3.57.56.5 Secondary23.327.126.1 Professional47.728.933.5 Higher25.636.533.8Income, %0.005 \<300 €/month16.725.323.2 300--550 €/month36.948.245.5 550--750 €/month28.618.320.8 \>750 €/month17.98.210.6Asthma medication, % Corticosteroids62.863.463.31.00 Corticosteriods + beta 2 mimetic33.733.233.31.00Poor asthma control, %62,86665,30.604Poor treatment adherence, % Morisky scale72.169.470.10.686 MARS (5-item) scale58.168.766.10.089 MARS (10-item) scale75.66970.60.278

The majority of the patients had professional education and were earning at least 300 euros per month. Two out of three patients were using corticosteroids and one third a combination therapy consisting of corticosteroids and a beta 2 mimetic drug. The prevalence of poor asthma control was 63% in men and 66% in women. The prevalence of poor treatment adherence ranged between 58--76% in men and 69% in women. Age, income, and education were statistically significantly differently distributed between men and women.

Table [2](#Tab2){ref-type="table"} shows the associations of the different asthma medication adherence scores with poor asthma control in the study sample. None of the three adherence scores was able to predict poor disease control in Latvian asthma patients.Table 2Associations of different asthma medication adherence scores with poor asthma controlUnivariateMultivariate^a^OR(95% CI)OR(95% CI)Men MARS (5-item)0.39(0.15--1.00)0.36(0.12--1.09) MARS (10-item)1.05(0.38--2.90)1.41(0.43--4.65) Morisky1.02(0.38--2.69)1.48(0.49--4.50)Women MARS (5-item)1.04(0.60--1.79)1.2(0.67--2.17) MARS (10-item)1.68(0.98--2.87)1.61(0.91--2.86) Morisky1.09(0.63--1.89)0.94(0.52--1.70)All MARS (5-item)0.81(0.51--1.30)0.87(0.52--1.44) MARS (10-item)1.5(0.93--2.40)1.43(0.87--2.36) Morisky1.07(0.67--1.72)0.99(0.60--1.66)\>6 (MARS-5), \>14 (MARS-10), \>1 (MMAS) was used to define poor medical adherence; ≤19 for the ACT was defined to indicate poorly controlled asthma*OR* odds ratio, *CI* confidence interval^a^ Adjusted for age, education and income

None of the socio-demographic or socio-economic factors were predictors of poor treatment adherence according to the Morisky or the MARS 10-item scale (Table [3](#Tab3){ref-type="table"}). Further adjustment did not change the findings of the unadjusted model.Table 3Associations of socio-demographic and socio-economic factors with poor treatment adherence in asthma patientsMorisky scaleMARS (5-item)MARS (10-item)UnadjustedAdjusted^a^UnadjustedAdjustedUnadjustedAdjustedOR(95% CI)OR(95% CI)OR(95% CI)OR(95% CI)OR(95% CI)OR(95% CI)Age1(0.98--1.01)1(0.98--1.01)0.98(0.97--1.00)0.98(0.96--0.99)1(0.99--1.02)1(0.98--1.01)Female sex0.88(0.51--1.50)0.86(0.48--1.54)1.58(0.96--2.60)1.87(1.07--3.27)0.72(0.41--1.26)0.65(0.35--1.18)Education Basic or secondary1Ref^b^1Ref1Ref1Ref1Ref1Ref Professional1.43(0.82--2.51)1.55(0.86--2.78)1.79(1.03--3.11)1.91(01.05--3.45)1.23(0.69--2.17)1.15(0.63--2.08) Higher1.45(0.83--2.53)1.72(0.92--3.22)1.27(0.75--2.16)1.25(0.68--2.29)0.97(0.56--1.69)1.16(0.62--2.17)Income \<300 €/month1Ref1Ref1Ref1Ref1Ref1Ref 300--550 €/month0.83(0.45--1.52)0.74(0.40--1.38)0.86(0.48--1.55)0.89(0.48--1.65)0.86(0.46--1.58)0.81(0.43--1.53) 550--750 €/month0.67(0.33--1.34)0.51(0.24--1.09)0.8(0.41--1.59)0.66(0.31--1.43)0.62(0.31--1.26)0.54(0.25--1.17) \>750 €/month1.27(0.50--3.22)0.92(0.33--2.54)0.87(0.38--2.03)0.75(0.29--1.93)0.77(0.32--1.84)0.64(0.25--1.69)Asthma medication Corticosteroids1.34(0.83--2.16)0.82(0.49--1.36)0.57(0.35--0.91)0.56(0.33--0.93)0.69(0.42--1.12)0.72(0.43--1.21) Corticosteriods + beta 2 mimetic1.04(0.64--1.69)0.85(0.51--1.41)1.93(1.18--3.16)2.04(1.19--3.49)1.18(0.72--1.93)1.11(0.66--1.86)*OR* odds ratio, *CI* confidence interval^a^ Adjusted for age, sex, education and income^b^ Reference group

However, when the Medication Adherence Reporting Scale (MARS) 5-item scale was used, increasing age (odds ratio (OR) 0.98 (95% confidence interval (CI) 0.97--1.00) and monotherapy with corticosteroids (OR 0.57; 95% CI 0.35--0.91) reduced the odds of poor treatment adherence. Moreover, professional education level (OR 1.79; 95% CI 1.03--3.11) or the combined use of corticosteroids and beta 2 mimetics (OR 1.93; 95% CI 1.18--3.16) increased the odds of poor treatment adherence.

The associations of cognitive and emotional illness indicators and poor treatment adherence measured using three different scores in asthma patients in Latvia are presented in Table [4](#Tab4){ref-type="table"}. None of the eight items of the brief Illness Perception Questionnaire (Brief IPQ) was a statistically significant predictor of poor treatment adherence in any of the three adherence scores. Adjustment for age, education or income did not alter the results.Table 4Associations of cognitive and emotional illness indicators and poor treatment adherence measured using three different scores in asthma patients in LatviaMorisky scaleMARS (5-item)MARS (10-item)UnadjustedAdjusted^a^UnadjustedAdjustedUnadjustedAdjustedOR(95% CI)OR(95% CI)OR(95% CI)OR(95% CI)OR(95% CI)OR(95% CI)How much does your illness affect your life?0.98(0.90--1.07)0.99(0.89--1.08)0.96(0.88--1.05)0.96(0.88--1.05)0.96(0.88--1.05)0.96(0.88--1.05)How long do you think your illness will continue?0.96(0.87--1.06)0.97(0.88--1.07)0.96(0.87--1.05)0.98(0.89--1.08)0.96(0.87--1.05)0.98(0.89--1.08)How much control do you feel you have over your illness?0.94(0.85--1.04)0.95(0.85--1.06)0.98(0.89--1.08)0.98(0.88--1.08)0.98(0.89--1.08)0.98(0.88--1.08)How much do you think your treatment can help your illness?0.99(0.89--1.10)1(0.89--1.12)0.96(0.86--1.07)0.96(0.85--1.07)0.96(0.86--1.07)0.96(0.85--1.07)How much do you experience symptoms from your illness?1.04(0.95--1.13)1.03(0.94--1.13)1.01(0.93--1.10)1.01(0.92--1.11)1.01(0.93--1.10)1.01(0.92--1.11)How concerned are you about your illness?1.02(0.95--1.10)1.03(0.96--1.11)0.99(0.93--1.07)1.01(0.94--1.09)0.99(0.93--1.07)1.01(0.94--1.09)How well do you feel you understand your illness?1.05(0.97--1.14)1.05(0.96--1.14)1.06(0.98--1.15)0.98(0.97--1.15)1.06(0.98--1.15)1.05(0.97--1.15)How much does your illness affect you emotionally?(e.g. does it make you angry, scared, upset or depressed?)1.03(0.97--1.11)1.05(0.98--1.13)1.03(0.96--1.10)1.03(0.96--1.11)1.03(0.96--1.10)1.03(0.96--1.11)*OR* odds ratio, *CI* confidence interval^a^ Adjusted for age, education and income

Whereas beliefs about medication were not associated with poor treatment adherence on the MARS 10-item scale, several questions about necessity or concerns related to pharmaceutical treatment were able to predict poor adherence according to the Morisky scale (Table [5](#Tab5){ref-type="table"}).Table 5Associations between medications believes and poor treatment adherence measured using three different scores in asthma patients in LatviaMorisky scaleMARS (5-item)MARS (10-item)UnadjustedAdjusted^a^UnadjustedAdjustedUnadjustedAdjustedOR(95% CI)OR(95% CI)OR(95% CI)OR(95% CI)OR(95% CI)OR(95% CI)Necessity My health is fully dependent on the asthma medication0.67(0.41--1.10)0.67(0.40--1.12)0.58(0.36--0.94)0.61(0.37--1.01)1.07(0.67--1.73)1.03(0.63--1.70) Without asthma medication my life would be impossible0.53(0.33--0.85)0.54(0.33--0.89)0.64(0.41--1.01)0.62(0.38--1.01)0.99(0.62--1.55)0.92(0.56--1.50) Without my asthma medication I would be very ill0.59(0.36--0.96)0.61(0.36--1.02)0.71(0.45--1.12)0.72(0.44--1.19)0.88(0.55--1.41)0.85(0.52--1.40) My future health depends on my asthma medication0.53(0.31--0.90)0.56(0.32--0.97)0.42(0.25--0.70)0.42(0.24--0.74)0.64(0.38--1.07)0.58(0.34--1.01) Controlling my asthma medication prevents health deteriation0.58(0.30--1.09)0.66(0.34--1.27)0.51(0.28--0.96)0.61(0.32--1.17)0.53(0.28--1.02)0.53(0.27--1.05)Concerns I am concerned by the need to constantly use my asthma medication2.03(1.24--3.30)1.96(1.19--3.24)1.69(1.07--2.68)1.59(0.98--2.57)1.36(0.84--2.18)1.33(0.82--2.16) I am sometimes concerned by long-term effects of my asthma medication2.3(0.27--0.71)2.43(1.45--4.08)1.89(1.19--3.01)2(1.22--3.27)1.44(0.89--2.31)1.48(0.90--2.42) My asthma medication is incomprehensible to me2.01(1.06--3.78)1.97(1.02--3.80)1.03(0.60--1.79)1.27(0.70--2.29)0.86(0.49--1.50)0.81(0.45--1.46)*OR* odds ratio, *CI* confidence interval^a^ adjusted for age, education and income

If the patient felt that without his asthma medication his/her life would be impossible, his risk to have poor treatment adherence was 46% reduced (OR 0.54; 95% CI 0.33--0.89). Furthermore, asthma patients who were convinced that their health depends on the asthma treatment were less likely to have poor treatment adherence (OR 0.56: 95% CI 0.32--0.97). Each of the three concerns about medication questions was a statistically significant predictor of poor treatment adherence. In case the patient was concerned by the need to constantly use asthma medication or sometimes concerned by long-term effects of their asthma medication the odds of poor treatment adherence were 1.96 (95% CI 1.19--3.24) and 2.43 (95% CI 1.45--4.08), respectively. Furthermore, patients who felt that their asthma medication is incomprehensible to them had a two-fold increase in risk of poor treatment adherence. In regard MARS 5-item scale, only two variables were able to predict poor treatment adherence. The risk of poor adherence was 58% reduced (95% CI 0.24--0.74) if the patients felt that their future health depends on their asthma medication. In addition, concerns about long-term effects of asthma medication increased the risk of poor treatment adherence two-fold (95% CI 1.22--3.27).

Discussion {#Sec3}
==========

Main findings {#Sec4}
-------------

This study found that socio-economic, socio-demographic or illness perceptions were not associated with poor asthma treatment adherence in Latvia patients. However, we revealed that concerns about the use of asthma medication and several beliefs about the necessity of asthma medication were able to predict poor treatment adherence when assessed by the Morisky or MARS 5-item adherence scales. Finally, the high prevalence of poor asthma control and treatment adherence in Latvian asthma patients is a great concern.

Interpretation of findings in relation to previously published work {#Sec5}
-------------------------------------------------------------------

Our findings revealing that two out of three Latvian asthma patients have poor disease control are in line with previous findings indicating a prevalence of 49--76% of poor asthma control in the European population.^[@CR14]--[@CR18]^ Furthermore, good asthma control seemed to be more difficult to achieve in asthmatic adults who had used corticosteroids (ICS) in the last 12 months compared with those who were not in need of inhaled corticosteroids.^[@CR15]^ The three treatment adherence scales used in this study revealed that close to seven out of ten asthma patients in Latvia have poor treatment adherence. Unlike poor asthma control, the prevalence of poor adherence in Latvian is considerably higher than reported in other European patient populations.^[@CR19]--[@CR21]^ For instance, poor adherence to asthma medication was found to be between 30--40% in France, Germany, and Italy.^[@CR19]^

The health belief model tries to explain how beliefs about medicines affect ones behavior to take medication proposing that a patient chooses a certain behavior through a cost-benefit analysis where the perceived benefits such as health improvements are compared against the perceived costs.^[@CR22],\ [@CR23]^ Unclear results have been published about whether necessity, concerns and the necessity-concern differential correlate with adherence in asthma patients.^[@CR24]--[@CR27]^ In contrast to our results, some studies assessing the associations of necessity, concerns and medication adherence in asthma patients revealed that only necessity beliefs were associated to medication adherence.^[@CR24],\ [@CR25]^

Byer et al. found that self-reported adherence was significantly positively correlated with the necessity in 64 asthma patients were from a general practice in Leicester, UK.^[@CR24]^ In addition, unlike our results they also reported a correlation between illness perception and medical adherence. Another study in 93 patients aged 18--80 years who filled at least two ICS prescriptions showed that necessities were positively related to self-reported adherence suggesting that it could be more important to focus on necessities than on concerns in an attempt to improve adherence.^[@CR25]^ In line with our results, other studies Menckeberg et al. showed a positive relationship between the necessity-concerns differential and adherence indicating that having stronger beliefs about the necessity of treatment compared to concerns about negative consequences may increase adherence.^[@CR26],\ [@CR27]^

A possible explanation of the contradictory results may be related to the power of the study. Most of the previous studies had a much lower sample size lacking power to detect an association between concerns and medical adherence given that most likely the association between necessity and medical adherence may be stronger than for concerns and adherence. A recent meta-analysis suggested that necessity and concern beliefs about medicines are one important factor to consider when understanding reasons for non-adherence in chronic disease patients.^[@CR28]^ Furthermore, they highlighted that the effect size for necessity was stronger in asthma and weaker in the cardiovascular group compared to the overall effect size. However, this may also reflect the difference in symptomatic vs. asymptomatic conditions of the diseases. An earlier meta-analysis by Horne et al. found a statistical significant association between necessity and concern beliefs and medication adherence even when stratified by country, sample size and type of adherence measure used.^[@CR29]^

It was of surprise that the combined use of corticosteroids and beta 2 mimetics using the MARS (5-item) showed a lower adherence than corticosteroids as it would have been expected that the clinical effect of combination therapy would favor adherence. As this finding was only observed in the MARS (5-item) and not in the Morisky Medication Adherence Scale (MMAS) or MARS (1-item), we hypothesize that the MARS (5-item) may be confounded by the additional elements/dimensions included in the other two scales.

There are many self-report scales for measuring medication adherence. Due to the different nature of the diseases, there is no gold standard scale for measuring medication adherence.^[@CR30]^ Our study showed the best associations between the necessity-concern framework with the Morisky scale but not with the MARS scale. The MARS scale has revealed adequate reliability but its validity seems to be only moderate-weak.^[@CR30],\ [@CR31]^ It has been suggested that though the internal consistency of the MARS could be improved either by adding more response options or by adding more items, it is debatable whether this would constitute an improvement to the measure, or whether it would compromise its quick, simple format.^[@CR30]^ According to our results, we suggest to use the Morisky scale in Latvian asthma patients as a tool to assess medical adherence.

Strengths and limitations of this study {#Sec6}
---------------------------------------

Our study had several limitations that need to be considered. Asthma medication adherence was measured by self-report questionnaires not previously validated in the Latvian population. Even though the MMAS and the MARS 10-item scales have been successfully validated in other studies,^[@CR32]--[@CR35]^ self-reported measurements of medication adherence may not be that precise and still subject to self-presentational and recall bias overestimating adherence. However, the MMAS and the MARS 10-item scales have been successfully validated in other studies.^[@CR32]--[@CR35]^ Furthermore, asthma control was measured by a self-administered questionnaire. Clinical measurements of asthma control may be more precise and objective. However, the asthma control test (ACT) has been successfully validated in other studies consisting of a similar population than ours and has shown to be well correlated with baseline percent predicted forced expiratory volume.^[@CR36]^ Thus, the ACT may correlate well with forced expiratory volume in the Latvian population as well. Furthermore, even though the patients of this study were recruited from the main towns and the capital city where the majority of the Latvian population live, the results cannot be generalized to the overall population of Latvian asthma patients. Moreover, it has to be mentioned that a general issue not addressed by self-reported adherence questionnaires is inhaler technique which is an essential part of good adherence implementation (14). The challenges faced when using inhaled medications can include a combination of delivery issues (e.g., knowing the sequence of steps required to use the inhaler correctly, successful dose preparation, inspiratory flow rate, and in pressurized metered-dose inhalers, dose actuation and coordination with breath inhalation); practical issues (e.g., integration and scheduling with coexisting medications, storage, and device cleaning); and psychosocial challenges (e.g., self-consciousness about inhaler use in public).^[@CR14],\ [@CR37],\ [@CR38]^ Thus, it may be worthwhile developing and validating treatment adherence questionnaires that consider these important factors. Finally, the findings of our study may only be valid for a more severe patient population: those patients referred to a pulmonologist and, thus, do not necessary represent those seen in regular primary health-care. These patients may already have some issues in regard adherence as it is the most common cause of control.

Implications for future research, policy and practice {#Sec7}
-----------------------------------------------------

Moreover, future studies are needed to validate the different asthma adherence scores, asthma control scores and other relevant self-assessment tools in a larger sample of Latvian asthma patients to improve their performance and utility.

Conclusions {#Sec8}
===========

In conclusion, none of the tested asthma treatment adherence scales were able to predict poor asthma control in Latvian patients. However, medication beliefs, particularly concerns and necessity of asthma treatment were associated with poor treatment adherence when assessed with the Morisky or 5-item MARS scale. Therefore, we recommend to use either the MMAS or the 5-item MARS scale in Latvian asthma patients to identify patients with poor treatment adherence. Thus, it may be worthwhile to assess routinely the concerns and necessity of asthma medication in patients within the Latvian health-care system to improve treatment adherence in that vulnerable population group to improve treatment outcomes.

Methods {#Sec9}
=======

Study population {#Sec10}
----------------

The study population of this cross-sectional patient survey consisted of asthma patients attending outpatient pulmonologist consultations in Riga, Latvia during September 2013 to December 2015. Latvian patients in most cases will receive their initial disease diagnosis and treatment initiation in a pulmonologist practice. They get there in larger part by a referral by a general practitioner (GP) or by direct patient contact. The majority of GPs refer their asthma and chronic obstructive pulmonary disease patients to a specialist at least once a year for control. The role of GPs within the Latvian health care system is mainly to ensure that a patient follows the treatment regime set forth by the specialist. Only patients referred by a GP to a National Health Service (NHS) registered practice can get their medication reimbursed by NHS. In a first step, a list of all pulmonologists from the database of the NHS of the medical doctors that have contractual rights to prescribe reimbursed medicines was acquired. Then, pulmonologists in large medical centers and hospitals in Riga and in bigger towns of Latvia were randomly selected and invited to join the study. The total number of participating pulmonologist practices was 15. Each pulmonologist was advised to invite his patients to join the survey. The sample size was calculated to detect a prevalence of poor asthma control of 50% with a margin of error of 5%, and a power of 95%. The total sample size needed and respectively studied was 352 people. Only patients that have been using asthma medication for at least one year were included in this study.

Assessment of main variables {#Sec11}
----------------------------

A self-administered questionnaire was used to assess socio-demographic and economic factors such as age, education, income, and sex. The patients filled in the questionnaire right after their visit with the doctor.

Adherence to asthma medication was assessed using MMAS and two different versions of MARS. The MMAS is a self-report tool, it was used to assess asthma medication adherence.^[@CR7]^ The MMAS is an eight item questionnaire that measures medication compliance on a scale of 0--11, with lower scores indicating greater adherence. The total MMAS score was obtained by summing ratings for all scale items. Seven items were answered by either yes (score = 1) or no (score = 0) responses, and one item was assessed using 5 point Likert-type responses ranging from "usually" to "all the time" (usually = 0; all the time = 4). The MMAS has been used across many chronic diseases, including asthma, as a self-reported measure of adherence to medications and has demonstrated good reliability and predictive validity.^[@CR32],\ [@CR33]^ The long version of the MARS is a validated 10-item questionnaire that has shown to have good internal, construct, and criterion validity, including correlations with objective measures of adherence (electronic monitoring and pharmacy dispensing data).^[@CR8],\ [@CR26]^ The MARS contains items that measure intentional ("I avoid using it if I can") and unintentional ("I forget to use it") nonadherence and these questions are phrased such that nonadherence is considered common to minimize social desirability bias. Medication use is rated on a 5-point Likert scale.^[@CR34],\ [@CR35]^ The short version of the MARS is a five-item self-report scale for assessment of adherent behavior that includes assessment of unintentional non-adherent behavior ("I forgot to take them", item 1) and intentional non-adherent behavior ("I alter the dose", item 2. "I stop taking them for a while", item 3. "I decide to miss out a dose", item 4. "I take less than instructed", item 5). Each item was answered using a five-graded response scale, ranging from very often (1) to never (5). Low scores indicate low levels of adherent behavior.^[@CR36]^

Good asthma control was assessed using the ACT, a validated five-item scale that reliably assesses asthma control over a recall period of 4 weeks. The ACT consists of the following questions: "How much of the time did your asthma keep you from getting as much done at work, school or at home?", "How often have you had shortness of breath?", "How often did your asthma symptoms wake you up at night or earlier than usual in the morning?", "How often have you used your rescue inhaler or nebulizer medication?" and "How would you rate your asthma control?".^[@CR39]^ Each item was scaled from 1 to 5, and by summing the response values a scale score was calculated ranging from poor (5) to total (25) control.^[@CR40],\ [@CR41]^ ACT scores have shown to be well correlated with baseline percent predicted forced expiratory volume.^[@CR41]^

Medication beliefs were assessed using the five items of greatest relevance to asthma medication adapted from the beliefs about medicines questionnaire (BMQ), a validated tool across many disease conditions.^[@CR22],\ [@CR42]^ The specific--necessity scale contains 5 items that assess patients' beliefs about specific necessity to take prescribed chronic medications. Three questions were selected from the six original items that assess patients' beliefs about specific necessity to take prescribed chronic medications. All belief items had Likert scale responses.

The Brief IPQ was used to obtain information on illness perception of the study participants. The Brief IPQ consists of eight items and a causal question.^[@CR43],\ [@CR44]^ All of the items except the causal question are rated using a 0-to-10 response scale. Five of the items assess cognitive illness representations: consequences (item 1), timeline (item 2), personal control (item 3), treatment control (item 4), and identity (item 5). Two of the items assess emotional representations: concern (item 6) and emotions (item 8). One item assesses illness comprehensibility (item 7). Assessment of the causal representation is by an open-ended response, which asks patients to list the three most important causal factors in their illness (item 9).

Statistical analysis {#Sec12}
--------------------

The Statistical Package for the Social Sciences (SPSS) IBM 21.0 was used to analyze the data. Means, standard deviations, and frequencies are presented to describe the characteristics of the study sample. A cutoff point of \>6 (MARS-5), \>14 (MARS-10), \>1 (MMAS) was used to define poor medical adherence. These cut-off points were chosen according to the ones proposed in previous studies.^[@CR7],\ [@CR8],\ [@CR26],\ [@CR34]--[@CR36]^ A cut-off point of ≤19 for the ACT was defined to indicate poorly controlled asthma, and scores of 20 points or more corresponded to well-controlled asthma.^[@CR40],\ [@CR41]^ The answers of the BMQ were dichotomized into (i) "I agree/I completely agree" and (ii) "Not sure/I disagree/I completely disagree". The logistic regression analysis were first conducted for each variable alone. In the multivariate logistic analysis the outcome variable was controlled for age, income, and educational level. The odds ratio and respective 95% CI are presented for all models. The validity of each logistic regression models were assessed by the Hosmer/Lemeshow test.
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